News

Cancer stem cells caught
Enlarge image

ScienceBelgiumUK

Cancer stem cells caught

06.08.2012 - Belgian and UK researchers have for the first time tracked the existence of cancer stem cells in vivo. The study provides another piece of evidence that cancer stem cells are drivers of tumour recurrence.

The study published in Nature demonstrates for the first time the existence of cancer stem cells during unperturbed solid tumour growth. The team led by Cédric Blanpain from Université libre de Bruxelles found specific subsets of cells in mouse tumours that seem to be responsible for the re-growth of tumours. These findings shed new light on the controversial issue of whether cancer stem cells exist in growing tumours and may have implications for potential therapies.

Cancer stem cells are proposed to be responsible for tumour recurrence after anti-cancer treatments fail. However, evidence for cancer stem cells in solid tumours remained unproven so far. Blanpain and co-workers tracked tumour progression in mouse model of skin cancer and observe a persistent subpopulation of tumour cells with stem-like properties. There are two more groups publishing in parallel on their tracking success of cancer stem cells in Nature and Science.

http://www.european-biotechnology-news.com/news/news/2012-03/cancer-stem-cells-caught.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • KARO BIO (S)33.00 SEK2042.86%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • SERODUS (N)2.92 NOK14.51%

FLOP

  • SYNGENTA (CH)309.90 CHF-18.19%
  • ZELTIA (E)3.35 EUR-12.76%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%

TOP

  • KARO BIO (S)33.00 SEK2029.0%
  • BIOTECH PHARMACON (N)12.40 NOK32.6%
  • TRANSGENE (F)3.82 EUR32.6%

FLOP

  • WILEX (D)1.95 EUR-44.3%
  • BIONOR PHARMA (N)1.21 NOK-41.8%
  • NORDIC NANOVECTOR (N)19.40 NOK-28.7%

TOP

  • KARO BIO (S)33.00 SEK3924.4%
  • ADOCIA (F)82.74 EUR408.9%
  • GALAPAGOS (B)53.36 EUR319.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.87 EUR-76.1%
  • NEOVACS (F)0.89 EUR-74.9%

No liability assumed, Date: 27.08.2015